MYRIAD GROUP AG |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - CHF | -.--% |
|
-27.92% | -62.93% |
| Apr. 11 | Syncona to Sell Stake in Portfolio Company to Century Therapeutics | MT |
| Feb. 20 | Syncona’s Takeover of Freeline Therapeutics Becomes Effective | MT |
| Sales 2016 | 14.68M 13.36M | Sales 2017 | 14.57M 13.25M | Capitalization | 105M 95.29M |
|---|---|---|---|---|---|
| Net income 2016 | -29M -26.38M | Net income 2017 | - 0 | EV / Sales 2016 | 17.6 x |
| Net cash position 2016 | 12.69M 11.54M | Net cash position 2017 | 21.39M 19.45M | EV / Sales 2017 | 5.72 x |
| P/E ratio 2016 |
-9.21
x | P/E ratio 2017 |
-70
x | Employees | - |
| Yield 2016 * |
-
| Yield 2017 |
-
| Free-Float | 47.9% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Peter McCormack
DFI | Director of Finance/CFO | 45 | 09-12-31 |
Bruce Jackson
CTO | Chief Tech/Sci/R&D Officer | 55 | 13-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leonardo de Luca
BRD | Director/Board Member | - | - |
Myriad Group AG is a Switzerland-based company. The Company provides mobile USSD technology, empowering enterprises to deliver new mobile services to enhance customer engagements and improve service delivery, regardless of device or connection. It products and services are integrated within mobile networks, exposing capabilities and core network assets to enterprises, offering unparalleled reach, security, and service.
Sector
Software
| 1st Jan change | Capi. | |
|---|---|---|
| -62.93% | 0 | |
| +6.14% | 3,004B | |
| -0.82% | 79.28B | |
| +2.89% | 77.94B | |
| -13.87% | 53.9B | |
| -19.47% | 50.22B | |
| +19.22% | 46.76B | |
| +7.42% | 39.49B | |
| +35.95% | 31.91B | |
| -12.64% | 23.99B |
- Stock Market
- Equities
- MYRN Stock
